Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$44.5M+3.5%-$46.14M-70.4%-$27.08M-120%-$12.3M-126%$46.89M
$2.03M-2.8%$2.09M-0.3%$2.1M-1.4%$2.13M+3.8%$2.05M-0.6%
$5.95M+38.1%$4.31M-1.3%$4.36M-10.8%$4.89M-7.6%$5.3M+18.6%
-$37.37M+13.1%-$43.01M-143%$100.43M+389%-$34.72M+23.7%-$45.49M-135%
$1.87M+144%$767K+17.8%$651K-61.6%$1.7M+6.8%$1.59M+767%
-$261M-301%-$65.07M-$100.23M-224%
$328.34M+1,008%$29.62M+8,413%$348K-4.7%$365K+2,507%$14K-97.7%
$29.97M+138%-$78.46M-$9.03M+93.8%-$145.71M-248%
-$39.24M+10.4%-$43.78M-144%$99.78M+374%-$36.42M+22.7%-$47.08M-137%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Monte Rosa Therapeutics, Inc. generate?
Monte Rosa Therapeutics, Inc. (GLUE) generated -$14.7M in operating cash flow over the trailing twelve months.
What is Monte Rosa Therapeutics, Inc.'s free cash flow?
After $5.0M of capital expenditures, Monte Rosa Therapeutics, Inc.'s free cash flow was -$19.7M over the trailing twelve months, down 164.5% year over year.
Where does Monte Rosa Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Monte Rosa Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.